American health regulator US Food and Drug Administration (US FDA) has issued a warning letter to Emcure Pharmaceuticals for violating current good manufacturing practice norms at its Pune-based plant.
The US Food and Drug Administration (FDA) has pulled up Aurobindo Pharma for ‘repeated’ violations in current good manufacturing practice (CGMP) at three of its plants in manufacturing certain active pharmaceutical ingredients (API) and intermediates.